--- title: "Prestige Brands | 8-K: FY2026 Q3 Revenue Misses Estimate at USD 283.44 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/274959802.md" datetime: "2026-02-05T11:07:28.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/274959802.md) - [en](https://longbridge.com/en/news/274959802.md) - [zh-HK](https://longbridge.com/zh-HK/news/274959802.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274959802.md) | [繁體中文](https://longbridge.com/zh-HK/news/274959802.md) # Prestige Brands | 8-K: FY2026 Q3 Revenue Misses Estimate at USD 283.44 M Revenue: As of FY2026 Q3, the actual value is USD 283.44 M, missing the estimate of USD 286.52 M. EPS: As of FY2026 Q3, the actual value is USD 0.97, missing the estimate of USD 1.16. EBIT: As of FY2026 Q3, the actual value is USD 93.16 M. ### Financial Performance Summary for Prestige Consumer Healthcare Inc. (普雷斯蒂奇) #### Revenue Prestige Consumer Healthcare Inc. (普雷斯蒂奇) reported quarterly revenue of $283.4 million for Q3 FY 26, a 2.4% decrease from $290.3 million in Q3 FY 25, with revenue excluding foreign currency decreasing by 2.2% year-over-year . Year-to-date revenue for FY 26 was $807.1 million, a 4.1% decline from $841.2 million in YTD FY 25 . Organic revenue for YTD FY 26 was down 3.9% year-over-year, primarily due to eye care supply constraints, though eCommerce sales showed strong growth . The International segment increased 4% excluding eye care supply constraints and foreign currency . #### Gross Profit and Margin Gross profit for Q3 FY 26 was $157.4 million, a 2.3% decrease from $161.0 million in Q3 FY 25, with the gross margin remaining flat at 55.5% compared to Q3 FY 25 . Year-to-date gross profit for FY 26 was $449.3 million, a 3.3% decrease from $464.5 million in YTD FY 25, while the year-to-date gross margin increased to 55.7% from 55.2% in YTD FY 25 . #### Operating Costs Advertising & Marketing (A&M) expenses for Q3 FY 26 increased by 5.6% to $40.1 million from $37.9 million in Q3 FY 25, representing 14.1% of total revenue . Year-to-date A&M was $113.7 million, a 4.2% decrease from $118.7 million in YTD FY 25, also representing 14.1% of total revenue . Adjusted General & Administrative (Adj. G&A) for Q3 FY 26 was $29.2 million, an 11.5% increase from $26.2 million in Q3 FY 25, accounting for 10.3% of total revenue . Year-to-date Adj. G&A was $85.7 million, a 5.6% increase from $81.2 million in YTD FY 25, representing 10.6% of total revenue . Depreciation & Amortization (excluding COGS D&A) for Q3 FY 26 was $5.1 million, a 3.8% increase from $5.0 million in Q3 FY 25 . Year-to-date D&A (excluding COGS D&A) was $15.5 million, a 4.5% decrease from $16.2 million in YTD FY 25 . #### Operating Income and Margin Operating income for Q3 FY 26 decreased by 9.8% to $83.0 million from $92.0 million in Q3 FY 25, resulting in an operating margin of 29.3%, down from 31.7% . Year-to-date operating income for FY 26 was $234.4 million, a 5.6% decrease from $248.3 million in YTD FY 25, with the operating margin at 29.0%, down from 29.5% . #### Adjusted EBITDA and Margin Adjusted EBITDA for Q3 FY 26 was $90.9 million, a 7.7% decrease from $98.5 million in Q3 FY 25, leading to an Adjusted EBITDA Margin of 32.1%, down from 33.9% . Year-to-date Adjusted EBITDA for FY 26 was $257.4 million, a 4.7% decrease from $270.0 million in YTD FY 25, with the year-to-date Adjusted EBITDA Margin at 31.9%, down from 32.1% . #### Net Income Net income for Q3 FY 26 was $46.7 million, down from $61.0 million in Q3 FY 25 . Year-to-date net income for FY 26 was $136.4 million, down from $164.5 million in YTD FY 25 . #### Cash Flow Free cash flow for Q3 FY 26 increased to $75.3 million from $63.5 million in Q3 FY 25 . Year-to-date free cash flow for FY 26 was $208.8 million, a 13% increase from $184.9 million in YTD FY 25 . Net cash provided by operating activities for Q3 FY 26 was $78.3 million, up from $65.1 million in Q3 FY 25 . Year-to-date net cash provided by operating activities for FY 26 was $214.8 million, up from $189.7 million in YTD FY 25 . #### Other Metrics Adjusted Diluted EPS for Q3 FY 26 was $1.14, a 6.6% decrease from $1.22 in Q3 FY 25 . Year-to-date Adjusted Diluted EPS for FY 26 was $3.16, a 1.3% decrease from $3.20 in YTD FY 25 . The company reported net debt of $1.0 billion at December 31, with a leverage ratio of 2.6x at the end of Q3 . Prestige Consumer Healthcare Inc. (普雷斯蒂奇) repurchased approximately $46 million in shares during Q3 and approximately $155 million year-to-date for about 2.3 million shares . The company also closed the Pillar5 acquisition in December . #### Outlook / Guidance (FY 26) Prestige Consumer Healthcare Inc. (普雷斯蒂奇) anticipates revenues of approximately $1,100 million for FY 26, with an expected organic revenue decline of about 3.0% and sequential improvement in Clear Eyes® shipments in Q4 . The company projects Adjusted Diluted EPS of approximately $4.54 and expects earnings growth to reaccelerate as revenue improves . The full-year free cash flow outlook remains unchanged at $245 million or more . ### Related Stocks - [Prestige Consumer Healthcare Inc. (PBH.US)](https://longbridge.com/en/quote/PBH.US.md) ## Related News & Research - [Thank you, seniors. Healthcare spending is pumping up economic and job growth.](https://longbridge.com/en/news/281661389.md) - [Breaking down the booming March jobs report](https://longbridge.com/en/news/281661049.md) - [Derivative Path and Wells Fargo Deliver FX Payments Solution for Community Banks | FBK Stock News](https://longbridge.com/en/news/281182296.md) - [VDC vs. IYK: Vanguard's Structural Advantage and IYK's Defensive Twist](https://longbridge.com/en/news/281591304.md) - [Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields](https://longbridge.com/en/news/281183048.md)